Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

NCT02243579 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Recurrent Mycosis Fungoides and Sezary Syndrome
Refractory Mycosis Fungoides and Sezary Syndrome
Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)